The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine
JS Ross, EA Slodkowska, WF Symmans… - The …, 2009 - academic.oup.com
Learning Objectives Contrast the current strengths and limitations of the three main slide-
based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer …
based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer …
[HTML][HTML] Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship
KJ Ruddy, EP Winer - Annals of oncology, 2013 - Elsevier
Background The causes, optimal treatments, and medical/psychosocial sequelae of breast
cancer in men are poorly understood. Design A systematic review of the English language …
cancer in men are poorly understood. Design A systematic review of the English language …
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
JS Ross, JA Fletcher, GP Linette, J Stec, E Clark… - The …, 2003 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Define
the historical background and biological basis of the discovery of the HER-2/neu gene and …
the historical background and biological basis of the discovery of the HER-2/neu gene and …
Breast cancer in men
SH Giordano, AU Buzdar… - Annals of internal …, 2002 - acpjournals.org
Purpose: Breast cancer in men is uncommon; 1500 new cases are diagnosed in the United
States yearly. Optimal management of breast cancer in men is unknown because the rarity …
States yearly. Optimal management of breast cancer in men is unknown because the rarity …
The myc oncogene: MarvelouslY complex
SK Oster, CSW Ho, EL Soucie, LZ Penn - 2002 - Elsevier
The activated product of the myc oncogene deregulates both cell growth and death check
points and, in a permissive environment, rapidly accelerates the affected clone through the …
points and, in a permissive environment, rapidly accelerates the affected clone through the …
[HTML][HTML] Targeted therapy in breast cancer: the HER-2/neu gene and protein
JS Ross, JA Fletcher, KJ Bloom, GP Linette… - Molecular & Cellular …, 2004 - ASBMB
The HER-2/neu oncogene, a member of the epidermal growth factor receptor or erb gene
family, encodes a transmembrane tyrosine kinase receptor that has been linked to prognosis …
family, encodes a transmembrane tyrosine kinase receptor that has been linked to prognosis …
FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters
The aim of this study was to evaluate the possible correlation between preoperative FDG-
PET results in human breast cancer and the prognostic markers Ki-67, c-erb B2, p53 …
PET results in human breast cancer and the prognostic markers Ki-67, c-erb B2, p53 …
Male breast cancer
C Gómez-Raposo, FZ Tévar, MS Moyano… - Cancer treatment …, 2010 - Elsevier
Male breast cancer accounts for around 1% of all breast cancer cases, but the incidence has
increased over the past 25years. The rarity of this entity precludes prospective randomized …
increased over the past 25years. The rarity of this entity precludes prospective randomized …
Male breast cancer: a review of clinical management
A Agrawal, AA Ayantunde, R Rampaul… - Breast cancer research …, 2007 - Springer
Aims Male breast cancer incidence is 1% of all breast cancers and is increasing. We aim to
present an overview of male breast cancer with particular emphasis on clinical …
present an overview of male breast cancer with particular emphasis on clinical …
Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review
S Chatterji, E Krzoska, CW Thoroughgood… - The Lancet …, 2023 - thelancet.com
Although similar phenotypically, there is evidence that male and female breast cancer differ
in their molecular landscapes. In this systematic review, we consolidated all existing …
in their molecular landscapes. In this systematic review, we consolidated all existing …